search
Back to results

A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Sitagliptin 100 mg/simvastatin 40 mg FDC
Metformin
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Has type 2 diabetes mellitus
  • Male, or female who is not of reproductive potential or if of reproductive potential agrees to abstain or use (or have their partner use) two acceptable methods of birth control during the study and for 14 days after the last dose of study drug
  • Currently on metformin monotherapy (>=1000 mg per day) for at least 4 weeks prior to study participation
  • Not on statin therapy or other lipid-lowering agent for at least 6 weeks prior to study participation

Exclusion Criteria:

  • History of type 1 diabetes mellitus or a history of ketoacidosis
  • History of 2 or more episodes of hypoglycemia resulting in seizure, coma or loss of consciousness over the past 3 months
  • On a thiazolidinedione (TZD) within the past 12 weeks
  • Has been treated with a statin or other lipid-lowering agent within 6 weeks prior to study participation
  • Is on or likely to require treatment with a prohibited medication (itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, verapamil, diltiazem, amlodipine, ranolazine, niacin)
  • Intends to consume >1.2 liters of grapefruit juice per day during the study
  • Is on or likely to require treatment for >=2 consecutive weeks or repeated courses of corticosteroids (inhaled, nasal and topical corticosteroids are permitted)
  • Is on a weight loss program and not in the maintenance phase or has started a weight loss medication or has undergone bariatric surgery within 12 months prior to study participation
  • Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study
  • History of myopathy or rhabdomyolysis with any statin
  • History of myocardial infarction, unstable or stable angina, angioplasty, bypass surgery, myocardial ischemia, peripheral artery disease, abdominal aortic aneurysm, transient ischemic attacks, stroke of carotid origin or >50% obstruction of a carotid artery
  • Diagnosis of congestive heart failure with New York Heart Association (NYHA) Class III or IV cardiac status
  • History of active liver disease (other than non-alcoholic steatosis) including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease
  • Chronic progressive neuromuscular disorder
  • Human immunodeficiency virus (HIV)
  • Hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • Currently being treated for hyperthyroidism or is on thyroid hormone replacement therapy and has not been on a stable dose for at least 6 weeks
  • History of malignancy <=5 years prior to study participation, except for basal cell or squamous cell skin cancer or in situ cervical cancer
  • Positive urine pregnancy test
  • Pregnant or breastfeeding, or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug
  • User of recreational or illicit drugs or has had a recent history of drug abuse
  • Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Sitagliptin 100 mg/simvastatin 40 mg FDC

    Arm Description

    Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.

    Outcomes

    Primary Outcome Measures

    Change From Baseline in Fasting Plasma Glucose (FPG)
    Change from baseline in FPG at Week 6 based on longitudinal data analysis (LDA) model including both baseline and post-baseline measurements as response variable and term time.
    Percentage of Participants Who Experienced at Least One Adverse Event
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.
    Number of Participants Who Discontinued Study Drug Due to an Adverse Event
    Participants who were discontinued from study drug due to an adverse event during the 6 weeks of treatment.

    Secondary Outcome Measures

    Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
    Change from baseline in LDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
    Change From Baseline in Total Cholesterol (TC)
    Change from baseline in TC was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
    Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)
    Change from baseline in non-HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
    Change From Baseline in Triglycerides (TG)
    Change from baseline in TG was measured as a percent change from baseline at Week 6 (median and distribution free 95% confidence interval).
    Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
    Change from baseline in HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.

    Full Information

    First Posted
    October 4, 2012
    Last Updated
    July 25, 2018
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01702298
    Brief Title
    A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
    Official Title
    An Open-label Study to Assess the Safety and Tolerability of MK-0431D for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    December 7, 2012 (Actual)
    Primary Completion Date
    May 29, 2013 (Actual)
    Study Completion Date
    May 29, 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to examine the safety and tolerability of sitagliptin 100 mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus with inadequate glycemic control on metformin.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    42 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Sitagliptin 100 mg/simvastatin 40 mg FDC
    Arm Type
    Experimental
    Arm Description
    Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.
    Intervention Type
    Drug
    Intervention Name(s)
    Sitagliptin 100 mg/simvastatin 40 mg FDC
    Other Intervention Name(s)
    MK-0431D
    Intervention Description
    Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
    Intervention Type
    Drug
    Intervention Name(s)
    Metformin
    Other Intervention Name(s)
    Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®
    Intervention Description
    Participants will continue pre-study dose of metformin tablet(s) >=1000 per day
    Primary Outcome Measure Information:
    Title
    Change From Baseline in Fasting Plasma Glucose (FPG)
    Description
    Change from baseline in FPG at Week 6 based on longitudinal data analysis (LDA) model including both baseline and post-baseline measurements as response variable and term time.
    Time Frame
    Baseline and Week 6
    Title
    Percentage of Participants Who Experienced at Least One Adverse Event
    Description
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.
    Time Frame
    Up to 8 weeks (including 14 days after final dose of study drug)
    Title
    Number of Participants Who Discontinued Study Drug Due to an Adverse Event
    Description
    Participants who were discontinued from study drug due to an adverse event during the 6 weeks of treatment.
    Time Frame
    Up to 6 weeks
    Secondary Outcome Measure Information:
    Title
    Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
    Description
    Change from baseline in LDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
    Time Frame
    Baseline and Week 6
    Title
    Change From Baseline in Total Cholesterol (TC)
    Description
    Change from baseline in TC was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
    Time Frame
    Baseline and Week 6
    Title
    Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)
    Description
    Change from baseline in non-HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
    Time Frame
    Baseline and Week 6
    Title
    Change From Baseline in Triglycerides (TG)
    Description
    Change from baseline in TG was measured as a percent change from baseline at Week 6 (median and distribution free 95% confidence interval).
    Time Frame
    Baseline and Week 6
    Title
    Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
    Description
    Change from baseline in HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.
    Time Frame
    Baseline and Week 6

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    79 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Has type 2 diabetes mellitus Male, or female who is not of reproductive potential or if of reproductive potential agrees to abstain or use (or have their partner use) two acceptable methods of birth control during the study and for 14 days after the last dose of study drug Currently on metformin monotherapy (>=1000 mg per day) for at least 4 weeks prior to study participation Not on statin therapy or other lipid-lowering agent for at least 6 weeks prior to study participation Exclusion Criteria: History of type 1 diabetes mellitus or a history of ketoacidosis History of 2 or more episodes of hypoglycemia resulting in seizure, coma or loss of consciousness over the past 3 months On a thiazolidinedione (TZD) within the past 12 weeks Has been treated with a statin or other lipid-lowering agent within 6 weeks prior to study participation Is on or likely to require treatment with a prohibited medication (itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, verapamil, diltiazem, amlodipine, ranolazine, niacin) Intends to consume >1.2 liters of grapefruit juice per day during the study Is on or likely to require treatment for >=2 consecutive weeks or repeated courses of corticosteroids (inhaled, nasal and topical corticosteroids are permitted) Is on a weight loss program and not in the maintenance phase or has started a weight loss medication or has undergone bariatric surgery within 12 months prior to study participation Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study History of myopathy or rhabdomyolysis with any statin History of myocardial infarction, unstable or stable angina, angioplasty, bypass surgery, myocardial ischemia, peripheral artery disease, abdominal aortic aneurysm, transient ischemic attacks, stroke of carotid origin or >50% obstruction of a carotid artery Diagnosis of congestive heart failure with New York Heart Association (NYHA) Class III or IV cardiac status History of active liver disease (other than non-alcoholic steatosis) including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease Chronic progressive neuromuscular disorder Human immunodeficiency virus (HIV) Hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) Currently being treated for hyperthyroidism or is on thyroid hormone replacement therapy and has not been on a stable dose for at least 6 weeks History of malignancy <=5 years prior to study participation, except for basal cell or squamous cell skin cancer or in situ cervical cancer Positive urine pregnancy test Pregnant or breastfeeding, or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug User of recreational or illicit drugs or has had a recent history of drug abuse Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
    IPD Sharing URL
    http://engagezone.msd.com/ds_documentation.php
    Available IPD and Supporting Information:
    Available IPD/Information Type
    CSR Synopsis
    Available IPD/Information URL
    http://www.merck.com/clinical-trials/study.html?id=0431D-312&kw=0431D-312&tab=access

    Learn more about this trial

    A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)

    We'll reach out to this number within 24 hrs